483
Roy F. ChemalyFDA 483 - Roy F. Chemaly - March 03, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Roy F. Chemaly, a clinical investigator in Houston, TX, revealed a significant compliance issue related to clinical trial conduct. The firm failed to report serious adverse events (SAEs) to the study sponsor within the timeframes specified by the study protocols. This indicates a critical lapse in patient safety reporting and adherence to regulatory requirements for investigational drug studies.
Open in Dashboard
ID · 6fac534a-ae9e-4f0a-8efe-6f01e4781596